Table 1.
Conditional suppression of neuroendocrine carcinogenesis by expression of an RB transgene in Rb+/− mice
| Neoplasia |
Rb+/−mice with tumor (%)*
|
Rb+/−RTgRB mice with tumor (%)†
|
Fisher’s P Tet(−) vs. Tet(+)‡ | ||
|---|---|---|---|---|---|
| Moribund | P140§ | Tet(−) | Tet(+) | ||
| Melanotroph tumor of the pituitary | 100 (41/41) | 100 (10/10) | 25 (3/12) | 100 (11/11) | 0.0003 |
| Tumor of the pituitary anterior lobe | 22 (9/41) | 19 (5/27) | ND | ND | |
| C-cell thyroid carcinoma | 95 (36/38) | 100 (7/7) | 17 (2/12) | 91 (10/11) | 0.006 |
| Parathyroid adenoma | 8 (3/39) | ND | ND | ND | |
| C-cell lung metastases | 68 (26/38) | 0 (0/11) | ND | ND | |
| Lung neuroendocrine hyperplasia | 11 (4/38) | ND | ND | ND | |
| Adrenal pheochromocytoma | 71 (22/31) | 78 (7/9) | 25 (3/12) | 73 (8/11) | 0.0391 |
| Islet of Langerhans hyperplasia | 41 (7/17) | ND | ND | ND | |
Numbers in parentheses indicate number of mice with tumor out of total number of mice.
Rb+/− mice in which expression of an RB transgene is repressed by tetracycline (Fig. 2); animals were treated with tetracycline from fertilization until either P90, Tet(−), or P140, Tet(+), killed on P140, and scored for tumors. ND, not determined. According to immunohistochemical and Western blotting analyses, no expression of RB was detected in tumors developing in Tet(−) group of Rb+/−RTgRB mice.
No significant difference in the frequencies of tumors was observed between Rb+/− mice and Rb+/− mice with either TgRBp-tTA or TghCMV*-1p-RB.
Both invasive tumors and EAPs are included.